In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Phenytoin | The metabolism of Cisapride can be increased when combined with Phenytoin. |
| Fosphenytoin | The metabolism of Cisapride can be increased when combined with Fosphenytoin. |
| Buprenorphine | Cisapride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cisapride. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Cisapride. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Cisapride. |
| Hydrocodone | Cisapride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Magnesium sulfate | The therapeutic efficacy of Cisapride can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Cisapride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Cisapride may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cisapride. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Cisapride. |
| Orphenadrine | Cisapride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Cisapride may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Cisapride. |
| Pramipexole | Cisapride may increase the sedative activities of Pramipexole. |
| Ropinirole | Cisapride may increase the sedative activities of Ropinirole. |
| Rotigotine | Cisapride may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Cisapride. |
| Sodium oxybate | Cisapride may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Cisapride may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Cisapride. |
| Thalidomide | Cisapride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Cisapride may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Erythromycin | The serum concentration of Cisapride can be increased when it is combined with Erythromycin. |
| Azithromycin | The serum concentration of Cisapride can be increased when it is combined with Azithromycin. |
| Roxithromycin | The serum concentration of Cisapride can be increased when it is combined with Roxithromycin. |
| Sirolimus | The serum concentration of Cisapride can be increased when it is combined with Sirolimus. |
| Dirithromycin | The serum concentration of Cisapride can be increased when it is combined with Dirithromycin. |
| Telithromycin | The serum concentration of Cisapride can be increased when it is combined with Telithromycin. |
| Candicidin | The serum concentration of Cisapride can be increased when it is combined with Candicidin. |
| Clarithromycin | The serum concentration of Cisapride can be increased when it is combined with Clarithromycin. |
| Josamycin | The serum concentration of Cisapride can be increased when it is combined with Josamycin. |
| Everolimus | The serum concentration of Cisapride can be increased when it is combined with Everolimus. |
| Epothilone D | The serum concentration of Cisapride can be increased when it is combined with Epothilone D. |
| Patupilone | The serum concentration of Cisapride can be increased when it is combined with Patupilone. |
| 6-Deoxyerythronolide B | The serum concentration of Cisapride can be increased when it is combined with 6-Deoxyerythronolide B. |
| Ixabepilone | The serum concentration of Cisapride can be increased when it is combined with Ixabepilone. |
| KOS-1584 | The serum concentration of Cisapride can be increased when it is combined with KOS-1584. |
| Ridaforolimus | The serum concentration of Cisapride can be increased when it is combined with Ridaforolimus. |
| Temsirolimus | The serum concentration of Cisapride can be increased when it is combined with Temsirolimus. |
| AVE9633 | The serum concentration of Cisapride can be increased when it is combined with AVE9633. |
| Coltuximab ravtansine | The serum concentration of Cisapride can be increased when it is combined with Coltuximab ravtansine. |
| Cethromycin | The serum concentration of Cisapride can be increased when it is combined with Cethromycin. |
| Mitemcinal | The serum concentration of Cisapride can be increased when it is combined with Mitemcinal. |
| Brefeldin A | The serum concentration of Cisapride can be increased when it is combined with Brefeldin A. |
| Solithromycin | The serum concentration of Cisapride can be increased when it is combined with Solithromycin. |
| Kitasamycin | The serum concentration of Cisapride can be increased when it is combined with Kitasamycin. |
| Carbomycin | The serum concentration of Cisapride can be increased when it is combined with Carbomycin. |
| Doramectin | The serum concentration of Cisapride can be increased when it is combined with Doramectin. |
| Eprinomectin | The serum concentration of Cisapride can be increased when it is combined with Eprinomectin. |
| Oleandomycin | The serum concentration of Cisapride can be increased when it is combined with Oleandomycin. |
| Selamectin | The serum concentration of Cisapride can be increased when it is combined with Selamectin. |
| Tildipirosin | The serum concentration of Cisapride can be increased when it is combined with Tildipirosin. |
| Tilmicosin | The serum concentration of Cisapride can be increased when it is combined with Tilmicosin. |
| Tylosin | The serum concentration of Cisapride can be increased when it is combined with Tylosin. |
| Tylvalosin | The serum concentration of Cisapride can be increased when it is combined with Tylvalosin. |
| Bryostatin 1 | The serum concentration of Cisapride can be increased when it is combined with Bryostatin 1. |
| Lorvotuzumab mertansine | The serum concentration of Cisapride can be increased when it is combined with Lorvotuzumab mertansine. |
| Epofolate | The serum concentration of Cisapride can be increased when it is combined with Epofolate. |
| Sagopilone | The serum concentration of Cisapride can be increased when it is combined with Sagopilone. |
| Troleandomycin | The serum concentration of Cisapride can be increased when it is combined with Troleandomycin. |
| Miocamycin | The serum concentration of Cisapride can be increased when it is combined with Miocamycin. |
| Flurithromycin | The serum concentration of Cisapride can be increased when it is combined with Flurithromycin. |
| Rokitamycin | The serum concentration of Cisapride can be increased when it is combined with Rokitamycin. |
| Midecamycin | The serum concentration of Cisapride can be increased when it is combined with Midecamycin. |
| Clindamycin | The serum concentration of Cisapride can be increased when it is combined with Clindamycin. |
| Mepartricin | The serum concentration of Cisapride can be increased when it is combined with Mepartricin. |
| Nelfinavir | The serum concentration of Cisapride can be increased when it is combined with Nelfinavir. |
| Indinavir | The serum concentration of Cisapride can be increased when it is combined with Indinavir. |
| Ritonavir | The serum concentration of Cisapride can be increased when it is combined with Ritonavir. |
| Amprenavir | The serum concentration of Cisapride can be increased when it is combined with Amprenavir. |
| Tipranavir | The serum concentration of Cisapride can be increased when it is combined with Tipranavir. |
| Atazanavir | The serum concentration of Cisapride can be increased when it is combined with Atazanavir. |
| Saquinavir | The serum concentration of Cisapride can be increased when it is combined with Saquinavir. |
| Darunavir | The serum concentration of Cisapride can be increased when it is combined with Darunavir. |
| Fosamprenavir | The serum concentration of Cisapride can be increased when it is combined with Fosamprenavir. |
| Lopinavir | The serum concentration of Cisapride can be increased when it is combined with Lopinavir. |
| Asunaprevir | The serum concentration of Cisapride can be increased when it is combined with Asunaprevir. |
| TMC-310911 | The serum concentration of Cisapride can be increased when it is combined with TMC-310911. |
| Amitriptyline | Amitriptyline may increase the arrhythmogenic activities of Cisapride. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Cisapride. |
| Mifepristone | The serum concentration of Cisapride can be increased when it is combined with Mifepristone. |
| Atomoxetine | The metabolism of Atomoxetine can be decreased when combined with Cisapride. |
| Brexpiprazole | The metabolism of Brexpiprazole can be decreased when combined with Cisapride. |
| Vortioxetine | The metabolism of Vortioxetine can be decreased when combined with Cisapride. |
| Cimetidine | The serum concentration of Cisapride can be increased when it is combined with Cimetidine. |
| Eliglustat | The metabolism of Eliglustat can be decreased when combined with Cisapride. |
| Iloperidone | The risk or severity of QTc prolongation can be increased when Cisapride is combined with Iloperidone. |
| Tetrabenazine | The metabolism of Tetrabenazine can be decreased when combined with Cisapride. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Cisapride. |
| Cobicistat | The risk or severity of QTc prolongation and Cardiac Arrhythmia can be increased when Cobicistat is combined with Cisapride. |
| Nifedipine | The serum concentration of Nifedipine can be increased when it is combined with Cisapride. |
| Simeprevir | The risk or severity of QTc prolongation and Cardiac Arrhythmia can be increased when Simeprevir is combined with Cisapride. |
| Telaprevir | The risk or severity of QTc prolongation and Cardiac Arrhythmia can be increased when Telaprevir is combined with Cisapride. |
| Phenindione | The risk or severity of adverse effects can be increased when Cisapride is combined with Phenindione. |
| Tioclomarol | The risk or severity of adverse effects can be increased when Cisapride is combined with Tioclomarol. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when Cisapride is combined with Ethyl biscoumacetate. |
| Diphenadione | The risk or severity of adverse effects can be increased when Cisapride is combined with Diphenadione. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when Cisapride is combined with 4-hydroxycoumarin. |